Target
gp100
10 abstracts
Abstract
A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301).Org: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Dermatology, University Hospital St. Pölten, Karl Landsteiner University of Health Sciences, Greenville Health System, Abindgon,
Abstract
A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial.Org: Bucks, Nottingham University Hospitals NHS Trust, Churchill Hospital, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Trust,
Abstract
Use of baseline and serial ctDNA dynamics to predict outcomes in patients treated with first-line tebentafusp, including those who were and were not treated beyond progression.Org: The Clatterbridge Cancer Centre and University of Liverpool,
Abstract
Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM).Org: Massachusetts General Hospital, UPMC Hillman Cancer Center, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, Columbia University Irving Medical Center, New York, NY, USA,
Abstract
Use of proteomimetic polymers for delivery of tumor antigens and adjuvants through formation of stable electrostatic complexes with small molecule STING agonists.Org: Medical Scientist Training Program, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, Evanston, IL,
Abstract
Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp.Org: Memorial Sloan Kettering Cancer Center, Immunocore Ltd., Massachusetts General Hospital, Institut Curie, Saint Cloud, France, Mount Vernon Cancer Center,
Abstract
A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).Org: UPMC Hillman Cancer Center, University of Oklahoma Stephenson Cancer Center, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Sidney Kimmel Cancer Center at Thomas Jefferson University,
Abstract
Real-world experience of tebentafusp for uveal melanoma via an Australian access program.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, The Kinghorn Cancer Centre, Darlinghurst, Australia,
Abstract
HLA discordance between blood and tumor: A treatment conundrum?Org: Sidney Kimmel Cancer Center at Thomas Jefferson University, Thomas Jefferson University, Philadelphia, PA,
Abstract
Tebentafusp (tebe) in a real-world cohort of 72 French metastatic uveal melanoma (UM) patients (pts).Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Institut Curie, Saint Cloud, France, APHP-INSERM U1149 Universite Paris Diderot, Curie Institute, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,